Skin & Beauty
What Causes Hair Shedding with PMDD?
Hair shedding during PMDD is more common than most clinicians acknowledge — yet it rarely shows up on a standard lab panel. The luteal-phase hormonal crash that defines PMDD can trigger a diffuse shedding cycle weeks after the worst mood symptoms have passed, making the connection easy to miss. Understanding the specific mechanisms behind PMDD-related hair loss is the first step toward fixing it.
What Causes Hair Shedding with PMDD?
Yes, PMDD can directly cause or worsen hair shedding. The sharp drop in progesterone and estrogen at the end of the luteal phase pushes hair follicles prematurely into the telogen (resting) phase, producing diffuse shedding two to four weeks later. The exception: if your hormones are well-supported and nutrient status is optimal, the effect is usually minor.
---
How PMDD Disrupts the Hair Growth Cycle
Premenstrual Dysphoric Disorder (PMDD) is not simply severe PMS. It is recognized as a distinct, cyclical neuroendocrine condition in DSM-5, driven by an abnormal sensitivity to normal luteal-phase fluctuations in estrogen and progesterone — not necessarily abnormally high or low hormone levels in absolute terms.
Hair follicles are highly responsive to sex hormones. Estrogen prolongs the anagen (active growth) phase, while the rapid estrogen withdrawal that characterizes the late luteal phase shortens it. Progesterone's mild androgenic metabolite, 5α-dihydroprogesterone, and — critically — allopregnanolone, modulate GABA-A receptors and have downstream effects on the hypothalamic-pituitary-adrenal (HPA) axis. When this axis is dysregulated each cycle, cortisol spikes during the luteal phase, and elevated cortisol is independently associated with premature follicle arrest (Thom 2016; PMID: 26574900).
The result is telogen effluvium: a form of diffuse hair shedding that occurs roughly 6–12 weeks after the physiological insult. Because this lag exists, most people with PMDD don't connect their cyclical shedding episodes to their menstrual pattern at all.
For a broader look at how hormonal cycling affects follicle health, see our guide on what causes hair shedding with PMS — many of the mechanisms overlap, though PMDD involves a more severe neuroendocrine response.
---
The Key Biomarkers Behind PMDD-Related Hair Loss
Before targeting supplements or protocols, it's worth identifying which biomarkers are actually out of range. The most clinically relevant ones for PMDD-associated hair shedding include:
| Biomarker | Optimal Range for Hair Health | Why It Matters in PMDD |
|---|---|---|
| Ferritin | ≥70 ng/mL | Low ferritin amplifies telogen effluvium; PMDD-related cycle irregularities increase blood loss risk |
| DHEA-S | Age-appropriate mid-range | Low DHEA-S correlates with HPA dysregulation and poor follicle androgen balance |
| Free T3 / TSH | TSH 1.0–2.5 mIU/L | Subclinical hypothyroidism is overrepresented in PMDD populations and independently causes shedding |
| Zinc (serum or RBC) | RBC zinc >190 µg/dL | Zinc is a 5-alpha reductase inhibitor; deficiency worsens androgenic follicle miniaturization |
| Vitamin D (25-OH) | 50–80 ng/mL | VDR receptors in follicle dermal papilla cells regulate cycling; PMDD correlates with low D |
| hs-CRP | <1.0 mg/L | Chronic low-grade inflammation disrupts anagen duration |
If you have PMDD alongside another hormonal condition, also read what causes hair thinning with PMDD and what causes hair shedding in perimenopause with hypothyroidism — the overlapping mechanisms matter for choosing the right protocol.
---
Inflammation as a Shared Driver
Chronic low-grade inflammation is elevated in PMDD. A 2017 study by Eisenlohr-Moul et al. found significantly higher inflammatory cytokine activity across the luteal phase in women with PMDD compared to controls (Eisenlohr-Moul et al., Psychoneuroendocrinology 2017; PMID: 28738191). Inflammatory cytokines — particularly IL-1β and TNF-α — directly shorten the anagen phase in human follicle organ culture models.
This creates a compounding cycle: PMDD causes inflammation; inflammation disrupts follicle cycling; follicle disruption produces shedding that worsens psychological distress; distress increases HPA reactivity and cortisol output; elevated cortisol feeds back into inflammation. Breaking any one link in this chain tends to benefit the others.
---
Glycine for Hair Growth
Glycine is not a flashy amino acid — it rarely appears in hair-supplement marketing — but the evidence for its role in follicle structure is solid. Collagen, which forms the bulk of the dermal papilla matrix and the follicle's connective tissue sheath, is approximately 33% glycine by composition. Without adequate glycine, collagen synthesis is rate-limited regardless of how much proline or hydroxyproline is available.
Beyond structural collagen, glycine is a co-agonist at NMDA receptors and is the primary substrate for glutathione synthesis alongside cysteine and glutamate. In PMDD specifically, glutathione depletion during the late luteal phase has been proposed as a mechanism linking oxidative stress to both mood symptoms and peripheral tissue damage — including follicle oxidative insult (Rapkin et al. 2014).
A 2022 review in Nutrients confirmed that glycine supplementation (in ranges of 3–10 g/day) significantly upregulates collagen gene expression and reduces inflammatory markers including IL-6 (Razak et al., Nutrients 2017; PMID: 28202621). For hair follicle applications, 3–5 g glycine daily alongside a vitamin C source to drive prolyl hydroxylase activity is a reasonable target. Glycine is also well-tolerated and has a mild sedative quality via glycinergic pathways — a potential secondary benefit for the sleep disruption that characterizes PMDD's luteal phase.
---
Beta-Alanine for Hair Growth
Beta-alanine is best known as a sports supplement for buffering muscle acidosis, but its relationship to hair growth is indirect and mechanistically interesting. Beta-alanine is a precursor to carnosine, a dipeptide (beta-alanine + histidine) found in high concentrations in tissues with rapid metabolic activity — including hair follicle matrix cells during active anagen.
Carnosine has documented antioxidant, anti-glycation, and metal-chelating properties. In follicle biology, advanced glycation end-products (AGEs) accumulate in the dermal papilla with age and inflammation, cross-linking the collagen matrix and impairing papilla cell signaling. Carnosine inhibits AGE formation and can break existing cross-links in vitro (Hipkiss 2009; PMID: 19662158).
In the context of PMDD, where oxidative stress is cyclically elevated, maintaining carnosine pools through adequate beta-alanine intake may help protect follicle papilla cells from luteal-phase oxidative bursts. Clinical doses for carnosine loading via beta-alanine are typically 3.2–6.4 g/day — the same ranges used in athletic performance research. Lower doses (1.6 g/day) sustain baseline tissue carnosine without meaningful anti-glycation benefit.
It's important to note that direct randomized controlled trials on beta-alanine supplementation for hair growth in humans have not yet been published. The proposed mechanism is biologically plausible but should be framed as adjunctive rather than primary.
---
Citrulline for Hair Growth
L-citrulline's relevance to hair health operates through nitric oxide (NO) signaling. Citrulline is converted to arginine in the kidneys, which then serves as substrate for nitric oxide synthase (NOS). NO is a potent vasodilator — and scalp microcirculation is a documented determinant of follicle nutrient delivery and anagen duration.
Beyond vascular effects, NOS is expressed directly in outer root sheath keratinocytes and in dermal papilla cells, where local NO production regulates hair follicle cycling (Lachgar et al., Journal of Investigative Dermatology 1996). Impaired scalp microcirculation is consistently observed in chronic telogen effluvium, and the cyclically elevated catecholamines and cortisol of PMDD are vasoconstrictive agents that can reduce scalp perfusion during the luteal phase.
L-citrulline is generally better absorbed than L-arginine at equivalent oral doses because it bypasses first-pass intestinal and hepatic arginine catabolism (Schwedhelm et al., British Journal of Clinical Pharmacology 2008; PMID: 18363766). Clinical doses for NO augmentation range from 3–6 g/day of L-citrulline or 6–8 g/day of citrulline malate. These are not hair-specific trial doses — they are extrapolated from cardiovascular and exercise physiology research — but the vascular mechanism is directly applicable to scalp perfusion.
---
Arginine for Hair Growth
Arginine is both the direct NOS substrate and a secretagogue for insulin-like growth factor 1 (IGF-1) in the dermal papilla. IGF-1 is one of the most well-established pro-anagen signals in follicle biology — it promotes keratinocyte proliferation and extends the growth phase, making it a target in androgenic alopecia and telogen effluvium research alike.
A key caveat: oral L-arginine is heavily catabolized in the gut by arginase before reaching systemic circulation, which limits its bioavailability relative to citrulline. That said, topical arginine delivery to the scalp bypasses this limitation entirely. Several hair growth formulations use topical arginine at 2–5% concentrations to locally stimulate NOS and vasodilate follicle vasculature without requiring systemic loading.
For systemic use, arginine doses of 3–6 g/day have been shown to raise plasma NO metabolites (NOx) measurably (Böger et al., Journal of Nutrition 1998; PMID: 9482769). Whether this systemic NO increase meaningfully improves scalp perfusion in the context of PMDD has not been directly tested, but given the documented scalp microvascular impairment in diffuse telogen effluvium, the mechanistic rationale is credible.
---
What This Means for Your Formula
For PMDD-related hair shedding, the most impactful supplement targets are those that address the hormonal-inflammatory cascade upstream, while the amino acids discussed above (glycine, citrulline, and arginine) work on follicle-level structure and perfusion as adjuncts.
Ones builds personalized daily capsule formulas calibrated to your blood work, wearable data, and health history. For someone flagging PMDD-associated hair shedding, a Ones formula would typically prioritize:
- Vitamin D3 + K2 (MK-7): Ones includes D3 + K2 in clinically relevant doses. A 2019 RCT found that vitamin D supplementation significantly improved hair follicle cycling markers in women with telogen effluvium and low 25-OH D levels (Almohanna et al., Dermatology and Therapy 2019; PMID: 30547302). VDR signaling in follicle cells is a direct anagen-promoting pathway.
- Zinc: Ones sources zinc in absorbable form at doses matching those used in clinical hair-loss research. Zinc inhibits 5-alpha reductase activity and supports follicle keratinocyte proliferation — especially relevant where androgenic sensitivity is elevated in the late luteal phase.
- Adrenal Support blend: Ones' proprietary Adrenal Support system blend is designed for HPA axis dysregulation — the central driver of the cortisol spikes that accelerate telogen effluvium in PMDD. Normalizing adrenal reactivity reduces one of the key upstream triggers of cyclical hair loss.
If your labs also flag low ferritin or subclinical thyroid findings, those would be addressed in a separate layer of the formula — Ones' AI practitioner treats the full biomarker picture rather than a single symptom in isolation.
---
Key Takeaways
- PMDD causes hair shedding primarily through luteal-phase hormone withdrawal that prematurely shifts follicles into the telogen (resting) phase, with a 6–12 week lag between trigger and visible shedding.
- Chronic low-grade inflammation elevated during the PMDD luteal phase — particularly IL-1β and TNF-α — directly shortens anagen duration independently of hormonal effects.
- The biomarkers most likely to drive PMDD-related hair shedding include low ferritin, low vitamin D, low zinc, and subclinical thyroid dysfunction — all correctable with targeted supplementation guided by lab results.
- Glycine (3–5 g/day) supports follicle collagen structure and antioxidant capacity; citrulline (3–6 g/day) and arginine improve scalp microcirculation via nitric oxide signaling; beta-alanine may protect papilla cells from glycation damage via carnosine.
- Hair shedding from PMDD is also frequently confused with other hormonal causes of shedding — getting a pattern diagnosis right matters before selecting a protocol.
- Personalized supplementation informed by blood work — addressing the upstream HPA, inflammatory, and nutritional drivers — offers the most reliable path to reducing cyclical PMDD-related hair shedding.
---
Always consult a qualified healthcare provider before beginning any supplementation protocol, particularly if you have a diagnosed hormonal condition or are currently taking medications.